Candidemia
Pipeline by Development Stage
On Market (1)
Approved therapies currently available
Competitive Landscape
9 companies ranked by most advanced pipeline stage
Trial Timeline
Clinical trial activity over time
Showing 15 of 21 trials with date data
Clinical Trials (22)
Total enrollment: 2,443 patients across 22 trials
A Study to Evaluate the Efficacy and Safety of Micafungin Against Invasive Candidiasis or Candidemia
Comparison of Candida Eradication and Serum Cidal Activity of Echinocandins
This Is An Open-Label, Non-Comparative Study Designed To Evaluate A Short Course Of IV Anidulafungin, Followed Optionally By Oral Voriconazole, For The Treatment Of Candidemia And Invasive Candidiasis
CRITIC - Treatment of Candidemia and Invasive Candidiasis
A Phase 3 Efficacy and Safety Study of Fosmanogepix for the Treatment of Adult Patients With Invasive Mold Infections.
A Phase 3 Efficacy and Safety Study of Fosmanogepix for the Treatment of Adult Participants With Candidemia and/or Invasive Candidiasis.
Anidulafungin In Treatment Of Candidemia In Asian Subjects
Open-label Study of APX001 for Treatment of Patients With Invasive Mold Infections Caused by Aspergillus or Rare Molds
An Open-label Study of APX001 for Treatment of Patients With Candidemia/Invasive Candidiasis Caused by Candida Auris
An Efficacy and Safety Study of APX001 in Non-Neutropenic Patients With Candidemia
A Study of Fosmanogepix in Healthy Adult Chinese Subjects
A Clinical Trial of the Study Medicine (Called Fosmanogepix) in Participants With Varying Degrees of Hepatic Function.
A Bioequivalence Study of APX001 High-load and Low-load Tablets
A Drug-Drug Interaction Study of CYP3A4 Inhibition and Pan-CYP Induction on APX001
A Study to Assess the Mass Balance Recovery and Metabolite Profile & Identification of [14C]-APX001 in Healthy Males
Safety and Pharmacokinetics of Intravenous and Oral APX001 in Patients With Acute Myeloid Leukemia (AML) and Neutropenia
Safety, Pharmacokinetics, Bioavailability, Food Effect, Drug-Drug Interaction Study of APX001 Administered Orally
Study to Assess Safety, Tolerability and Pharmacokinetics of APX001 Administered by Intravenous Infusion to Healthy Subjects
Expanded Access to Fosmanogepix for Patients With Serious or Life-threatening Invasive Fungal Infections
Post Marketing Surveillance Study To Observe Safety And Efficacy Of Eraxis® IV
Early- and Late-onset Candidemia
A Laboratory-based Surveillance Study of Candida Bloodstream Infections (MK-0991-093)
Phase Legend
Key Insights
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.